Patrick Daly

DocwireNews

In part one of the phase II/III RESILIENT trial, led by Luis Paz-Ares, researchers evaluated outcomes of second-line treatment with liposomal irinotecan in patients with small cell lung cancer (SCLC) who had disease progression during or after first-line platinum-based chemotherapy. According to the report, published in Cancer, “overall, no new safety signals were identified with liposomal irinotecan, and antitumor activity was promising.”
The first phase of the RESILIENT trial was comprised of dose-exploration and dose-expansion in a total cohort of 25 patients with SCLC. The primary objectives of the trial were to define the safety and tolerability profiles, and to identify a recommended dose. Primary efficacy endpoints were the objective response rate (ORR), progression-free survival (PFS), and overall survival (OS).
An initial dose of intravenous liposomal irinotecan 85 mg/m2 was judged not tolerable after exploration in five patients. Twelve patients received a 70 mg/m2 dose, which was deemed tolerable and used for the dose expansion phase, where 13 additional patients also received the indicated dose. Among these 25 patients, ten experienced grade III or higher treatment-related, treatment-emergent adverse events (TEAEs), the most common of which were diarrhea and neutropenia. Three patients experienced serious treatment related TEAEs, of which two died. Regarding efficacy, the ORR was 44% (95% confidence interval [CI], 24.40–65.07) and the median PFS and OS were 3.98 (95% CI, 1.45–4.24) and 8.08 months (95% CI, 5.16–9.82), respectively.
Given their results, the authors posited that “further evaluation of the efficacy and safety of liposomal irinotecan monotherapy at the recommended dose of 70 mg/m2 is warranted,” and pointed to the ongoing part two of the RESILIENT trial.

Andrew Moreno

Genetic Classification Model Differentiates MDS Stem, Progenitor Cells from Healthy Bone Marrow

ASH 2024

Cecilia Brown

FDA Grants Breakthrough Therapy Designation to Sacituzumab Govitecan for Second-Line Treatment of ES-SCLC

Small Cell Lung Cancer

Genetic Study Uncovers Potential Therapy-Actionable Transcription Factors in MDS

Latest News

RESILIENT Trial: Second-Line Liposomal Irinotecan in Small Cell Lung Cancer

In part one of the phase II/III RESILIENT trial, led by Luis Paz-Ares, researchers evaluated outcomes of second-line treatment with liposomal irinotecan in patients with small ...

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Hurricanes & Health Care

Career Center

Expert Interviews

Subscribe